BACKGROUND: The Children's Oncology Group (COG) adopted cisplatin, 5-flourouracil, and vincristine (C5V) as standard therapy after the INT-0098 legacy study showed statistically equivalent survival but less toxicity in comparison with cisplatin and doxorubicin. Subsequent experience demonstrated doxorubicin to be effective in patients with recurrent disease after C5V, and this suggested that it could be incorporated to intensify therapy for patients with advanced disease. METHODS: In this nonrandomized, phase 3 COG trial, the primary aim was to explore the feasibility and toxicity of a novel therapeutic cisplatin, 5-flourouracil, vincristine, and doxorubicin (C5VD) regimen with the addition of doxorubicin to C5V for patients considered to be at intermediate risk. Patients were eligible if they had unresectable, nonmetastatic disease. Patients with a complete resection at diagnosis and local pathologic evidence of small cell undifferentiated histology were also eligible for an assessment of feasibility. RESULTS: One hundred two evaluable patients enrolled between September 14, 2009, and March 12, 2012. Delivery of C5VD was feasible and tolerable: the mean percentages of the target doses delivered were 96% (95% CI, 94%-97%) for cisplatin, 96% (95% CI, 94%-97%) for 5-fluorouracil, 95% (95% CI, 93%-97%) for doxorubicin, and 90% (95% CI, 87%-93%) for vincristine. Toxicity was within expectations, with death as a first event in 1 patient. The most common adverse events were febrile neutropenia (n = 55 [54%]), infection (n = 48 [47%]), mucositis (n = 31 [30%]), hypokalemia (n = 39 [38%]), and elevated aspartate aminotransferase (n = 28 [27%]). The 5-year event-free and overall survival rates for the 93 patients who did not have complete resection at diagnosis were 88% (95% CI, 79%-93%) and 95% (95% CI, 87%-98%), respectively. CONCLUSIONS: The addition of doxorubicin to the previous standard regimen of C5V is feasible, tolerable, and efficacious, and this suggests that C5VD is a good regimen for future clinical trials.
BACKGROUND: The Children's Oncology Group (COG) adopted cisplatin, 5-flourouracil, and vincristine (C5V) as standard therapy after the INT-0098 legacy study showed statistically equivalent survival but less toxicity in comparison with cisplatin and doxorubicin. Subsequent experience demonstrated doxorubicin to be effective in patients with recurrent disease after C5V, and this suggested that it could be incorporated to intensify therapy for patients with advanced disease. METHODS: In this nonrandomized, phase 3 COG trial, the primary aim was to explore the feasibility and toxicity of a novel therapeutic cisplatin, 5-flourouracil, vincristine, and doxorubicin (C5VD) regimen with the addition of doxorubicin to C5V for patients considered to be at intermediate risk. Patients were eligible if they had unresectable, nonmetastatic disease. Patients with a complete resection at diagnosis and local pathologic evidence of small cell undifferentiated histology were also eligible for an assessment of feasibility. RESULTS: One hundred two evaluable patients enrolled between September 14, 2009, and March 12, 2012. Delivery of C5VD was feasible and tolerable: the mean percentages of the target doses delivered were 96% (95% CI, 94%-97%) for cisplatin, 96% (95% CI, 94%-97%) for 5-fluorouracil, 95% (95% CI, 93%-97%) for doxorubicin, and 90% (95% CI, 87%-93%) for vincristine. Toxicity was within expectations, with death as a first event in 1 patient. The most common adverse events were febrile neutropenia (n = 55 [54%]), infection (n = 48 [47%]), mucositis (n = 31 [30%]), hypokalemia (n = 39 [38%]), and elevated aspartate aminotransferase (n = 28 [27%]). The 5-year event-free and overall survival rates for the 93 patients who did not have complete resection at diagnosis were 88% (95% CI, 79%-93%) and 95% (95% CI, 87%-98%), respectively. CONCLUSIONS: The addition of doxorubicin to the previous standard regimen of C5V is feasible, tolerable, and efficacious, and this suggests that C5VD is a good regimen for future clinical trials.
Authors: Howard M Katzenstein; Max R Langham; Marcio H Malogolowkin; Mark D Krailo; Alexander J Towbin; Mary Beth McCarville; Milton J Finegold; Sarangarajan Ranganathan; Stephen Dunn; Eugene D McGahren; Gregory M Tiao; Allison F O'Neill; Muna Qayed; Wayne L Furman; Caihong Xia; Carlos Rodriguez-Galindo; Rebecka L Meyers Journal: Lancet Oncol Date: 2019-04-08 Impact factor: 41.316
Authors: Christopher B Weldon; Arin L Madenci; Gregory M Tiao; Stephen P Dunn; Max R Langham; Eugene D McGahren; Sarangarajan Ranganathan; Dolores H López-Terrada; Milton J Finegold; Marcio H Malogolowkin; Jin Piao; Li Huang; Mark D Krailo; Rebecka L Meyers; Howard M Katzenstein Journal: J Pediatr Surg Date: 2019-05-11 Impact factor: 2.545
Authors: Marcio H Malogolowkin; Howard Katzenstein; Mark D Krailo; Zhengjia Chen; Laura Bowman; Marleta Reynolds; Milton Finegold; Brian Greffe; Jon Rowland; Kurt Newman; Richard B Womer; Wendy B London; Robert P Castleberry Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: J A Ortega; E C Douglass; J H Feusner; M Reynolds; J J Quinn; M J Finegold; J E Haas; D R King; W Liu-Mares; M G Sensel; M D Krailo Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: Rebecka L Meyers; Greg Tiao; Jean de Ville de Goyet; Riccardo Superina; Daniel C Aronson Journal: Curr Opin Pediatr Date: 2014-02 Impact factor: 2.856
Authors: Giorgio Perilongo; Rudolf Maibach; Elisabeth Shafford; Laurence Brugieres; Penelope Brock; Bruce Morland; Beatriz de Camargo; Jozsef Zsiros; Derek Roebuck; Arthur Zimmermann; Daniel Aronson; Margaret Childs; Eva Widing; Veronique Laithier; Jack Plaschkes; Jon Pritchard; Marcello Scopinaro; Gordon MacKinlay; Piotr Czauderna Journal: N Engl J Med Date: 2009-10-22 Impact factor: 91.245
Authors: Howard M Katzenstein; Kay W Chang; Mark Krailo; Zhengjia Chen; Milton J Finegold; Jon Rowland; Marleta Reynolds; Alberto Pappo; Wendy B London; Marcio Malogolowkin Journal: Cancer Date: 2009-12-15 Impact factor: 6.860
Authors: József Zsiros; Laurence Brugieres; Penelope Brock; Derek Roebuck; Rudolf Maibach; Arthur Zimmermann; Margaret Childs; Daniele Pariente; Veronique Laithier; Jean-Bernard Otte; Sophie Branchereau; Daniel Aronson; Arun Rangaswami; Milind Ronghe; Michela Casanova; Michael Sullivan; Bruce Morland; Piotr Czauderna; Giorgio Perilongo Journal: Lancet Oncol Date: 2013-07-04 Impact factor: 41.316